Similarly, SGLT2Is outperform other antihyperglycemics in reducing levels of ALT (alanine transaminase), AST (aspartate transaminase), and FIB-4 (fibrosis-4 index for liver fibrosis). This evidence concerns the gene GPT and Hepatic fibrosis.